Market Cap 75.91M
Revenue (ttm) 0.00
Net Income (ttm) -134.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.23
Volume 69,900
Avg Vol 293,132
Day's Range N/A - N/A
Shares Out 54.22M
Stochastic %K 9%
Beta 0.53
Analysts Strong Sell
Price Target $3.00

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 466 7125
Address:
323 Allerton Avenue, South San Francisco, United States
HerdingBehavior
HerdingBehavior Dec. 25 at 3:51 PM
$ALXO Investors are recalibrating expectations as the balance shifts from vision to execution. Cost discipline must coexist with targeted investment. Evidence of resilience during turbulence would be constructive. Success from here is primarily about discipline, not discovery.
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Dec. 20 at 7:43 PM
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 12 at 12:00 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ALXO | Timeframe: 6M / 1D Market Cap: $82.41M • Pattern score: 0.67 • Current price: $1.520 • Peak (window): $2.180 • Trough (post-spike): $1.180 • Pullback: ~45.9% from peak • Move off lows: ~69.7% of peak Stock Plan (educational only) • Entry zone: $1.474 – $1.550 • Scalp target: $1.642 → Est. ROI: ~8.0% • Swing target: $1.744 → Est. ROI: ~14.7% • Protective stop: $1.292 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-16 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.550 → Exit target: ~$0.963 (≈+75% vs entry) → Protective stop: ~$0.330 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $BB
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 11 at 11:37 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ALXO | Timeframe: 6M / 1D Market Cap: $82.41M • Pattern score: 0.67 • Current price: $1.520 • Peak (window): $2.180 • Trough (post-spike): $1.180 • Pullback: ~45.9% from peak • Move off lows: ~69.7% of peak Stock Plan (educational only) • Entry zone: $1.474 – $1.550 • Scalp target: $1.642 → Est. ROI: ~8.0% • Swing target: $1.744 → Est. ROI: ~14.7% • Protective stop: $1.292 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-16 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.550 → Exit target: ~$0.963 (≈+75% vs entry) → Protective stop: ~$0.330 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $DJT
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 11 at 11:33 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ALXO | Timeframe: 6M / 1D Market Cap: $82.41M • Pattern score: 0.67 • Current price: $1.520 • Peak (window): $2.180 • Trough (post-spike): $1.180 • Pullback: ~45.9% from peak • Move off lows: ~69.7% of peak Stock Plan (educational only) • Entry zone: $1.474 – $1.550 • Scalp target: $1.642 → Est. ROI: ~8.0% • Swing target: $1.744 → Est. ROI: ~14.7% • Protective stop: $1.292 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-16 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.550 → Exit target: ~$0.963 (≈+75% vs entry) → Protective stop: ~$0.330 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $DJT
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Dec. 10 at 3:27 AM
$ALXO short interest has dropped from 6 mil shares April 30 to 793k shares Nov 28. They mass covered. They know what's coming here
0 · Reply
StarLord13
StarLord13 Dec. 8 at 6:49 PM
$ALXO Wow, going to close in the red. This stock is cooked!
1 · Reply
Wizzard88
Wizzard88 Dec. 8 at 6:26 PM
$ALXO Trash ! Going down with news 🤣
0 · Reply
Gabriel_DS
Gabriel_DS Dec. 8 at 6:22 PM
$ALXO what a joke
0 · Reply
StarLord13
StarLord13 Dec. 8 at 3:02 PM
$ALXO Lmao, sitting below Friday’s high even after releasing positive data. What a joke! 🤦‍♂️
0 · Reply
Latest News on ALXO
ALX Oncology to Present at Upcoming Investor Conferences

Nov 18, 2025, 11:00 AM EST - 5 weeks ago

ALX Oncology to Present at Upcoming Investor Conferences


ALX Oncology to Host Virtual R&D Day on March 5, 2025

Feb 18, 2025, 8:00 AM EST - 11 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025


ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation


ALX Oncology shares jump 9% after Jefferies upgrade

Dec 8, 2023, 8:30 AM EST - 2 years ago

ALX Oncology shares jump 9% after Jefferies upgrade


ALX Oncology Announces Pricing of Public Offering

Oct 5, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Announces Pricing of Public Offering


ALX Oncology Announces Proposed Public Offering

Oct 4, 2023, 4:10 PM EDT - 2 years ago

ALX Oncology Announces Proposed Public Offering


HerdingBehavior
HerdingBehavior Dec. 25 at 3:51 PM
$ALXO Investors are recalibrating expectations as the balance shifts from vision to execution. Cost discipline must coexist with targeted investment. Evidence of resilience during turbulence would be constructive. Success from here is primarily about discipline, not discovery.
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Dec. 20 at 7:43 PM
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 12 at 12:00 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ALXO | Timeframe: 6M / 1D Market Cap: $82.41M • Pattern score: 0.67 • Current price: $1.520 • Peak (window): $2.180 • Trough (post-spike): $1.180 • Pullback: ~45.9% from peak • Move off lows: ~69.7% of peak Stock Plan (educational only) • Entry zone: $1.474 – $1.550 • Scalp target: $1.642 → Est. ROI: ~8.0% • Swing target: $1.744 → Est. ROI: ~14.7% • Protective stop: $1.292 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-16 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.550 → Exit target: ~$0.963 (≈+75% vs entry) → Protective stop: ~$0.330 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $BB
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 11 at 11:37 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ALXO | Timeframe: 6M / 1D Market Cap: $82.41M • Pattern score: 0.67 • Current price: $1.520 • Peak (window): $2.180 • Trough (post-spike): $1.180 • Pullback: ~45.9% from peak • Move off lows: ~69.7% of peak Stock Plan (educational only) • Entry zone: $1.474 – $1.550 • Scalp target: $1.642 → Est. ROI: ~8.0% • Swing target: $1.744 → Est. ROI: ~14.7% • Protective stop: $1.292 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-16 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.550 → Exit target: ~$0.963 (≈+75% vs entry) → Protective stop: ~$0.330 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $DJT
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 11 at 11:33 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ALXO | Timeframe: 6M / 1D Market Cap: $82.41M • Pattern score: 0.67 • Current price: $1.520 • Peak (window): $2.180 • Trough (post-spike): $1.180 • Pullback: ~45.9% from peak • Move off lows: ~69.7% of peak Stock Plan (educational only) • Entry zone: $1.474 – $1.550 • Scalp target: $1.642 → Est. ROI: ~8.0% • Swing target: $1.744 → Est. ROI: ~14.7% • Protective stop: $1.292 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-16 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.550 → Exit target: ~$0.963 (≈+75% vs entry) → Protective stop: ~$0.330 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $DJT
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Dec. 10 at 3:27 AM
$ALXO short interest has dropped from 6 mil shares April 30 to 793k shares Nov 28. They mass covered. They know what's coming here
0 · Reply
StarLord13
StarLord13 Dec. 8 at 6:49 PM
$ALXO Wow, going to close in the red. This stock is cooked!
1 · Reply
Wizzard88
Wizzard88 Dec. 8 at 6:26 PM
$ALXO Trash ! Going down with news 🤣
0 · Reply
Gabriel_DS
Gabriel_DS Dec. 8 at 6:22 PM
$ALXO what a joke
0 · Reply
StarLord13
StarLord13 Dec. 8 at 3:02 PM
$ALXO Lmao, sitting below Friday’s high even after releasing positive data. What a joke! 🤦‍♂️
0 · Reply
topstockalerts
topstockalerts Dec. 8 at 2:59 PM
Alx Oncology reported impressive Phase 2 results for its cancer therapy evorpacept, showing a 92% complete response rate when combined with rituximab and lenalidomide (R2) in previously untreated indolent non-Hodgkin lymphoma patients—far exceeding the historical ~50% rate for R2 alone. In the 24-patient study presented at the ASH Annual Meeting, all patients responded, with 91% one-year progression-free survival and 100% overall survival. The treatment was well tolerated, and researchers will continue tracking minimal residual disease clearance over time. The trial was led by MD Anderson’s Dr. Paolo Strati, who previously observed promising results with the same combination in relapsed settings. $ALXO
0 · Reply
StarLord13
StarLord13 Dec. 8 at 2:36 PM
$ALXO that’s it? Needs to break the last recent high of 1.66 to change the daily trend back to bullish..
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 8 at 1:37 PM
$ALXO (+10.6% pre) ALX Oncology reports positive Phase 2 trial results for lymphoma treatment - SI https://ooc.bz/l/86602
0 · Reply
Stock__Hunter
Stock__Hunter Dec. 8 at 1:13 PM
$ALXO worth a watch .. right sector
0 · Reply
GoImugene
GoImugene Dec. 8 at 2:44 AM
$ALXO This is going to fly. Plus the novel EGFR ADC trial for the future readout. Way to cheap here.
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Dec. 8 at 2:13 AM
1 · Reply
Iorgi
Iorgi Dec. 8 at 1:57 AM
$ALXO What a surprise Sunday announcement. Like me, many didn't notice the news till now if at all. Not enough liquidity for a night move. It will be an exciting day tomorrow as the news spreads and liquidity improves.
0 · Reply
Iorgi
Iorgi Dec. 8 at 1:07 AM
$SMX $ALXO news. This one is gonna bust a huge move from these basement levels.
1 · Reply
AlertsAndNews
AlertsAndNews Dec. 7 at 10:54 PM
$ALXO ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting "Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 alone"
0 · Reply
TA_Kongen
TA_Kongen Dec. 7 at 8:01 PM
$ALXO Strongpoints:___ Extremely high 92% CR and 100% ORR Very clean safety Strong early durability (91% PFS at 1 year) Fits a chemo-free frontline paradigm attractive to patients and clinicians The effect size vs R² historical is large and visually impressive Considerations:___ No randomized control arm Small N (~24 pts) Only 1-year follow-up (indolent lymphomas need long-term durability to be meaningful) Frontline indolent lymphoma can naturally have good outcomes, which inflates apparent success of active regimens Does not inform how much of the effect is due specifically to evorpacept vs patient selection / biology
3 · Reply
MakingMoneyHere
MakingMoneyHere Dec. 7 at 5:34 PM
$ALXO https://www.stocktitan.net/news/ALXO/alx-oncology-announces-positive-results-from-ongoing-investigator-rnyo0hdta01w.html
0 · Reply
StarLord13
StarLord13 Dec. 5 at 3:59 PM
$ALXO Another lower high formed before another lower low. This is the 5th time it has rejected the 350ma (yellow line).
0 · Reply